Neuroimaging in bipolar disorder: what have we learned?
暂无分享,去创建一个
Deborah A Yurgelun-Todd | A. Stoll | P. Renshaw | D. Yurgelun-Todd | B. Cohen | Perry F Renshaw | Bruce M Cohen | Andrew L Stoll
[1] B. Woods,et al. Age-related MRI abnormalities in bipolar illness: A clinical study , 1995, Biological Psychiatry.
[2] S. Strakowski,et al. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. , 1998, The Journal of clinical psychiatry.
[3] N. Kato,et al. Magnetic resonance spectroscopy in affective disorders. , 1998, The Journal of neuropsychiatry and clinical neurosciences.
[4] Genetics and mental disorders. National Institute of Mental Health's Genetics Workgroup. , 1999, Biological psychiatry.
[5] Klaus P. Ebmeier,et al. Limbic Dysfunction in Schizophrenia and Mania , 1996, British Journal of Psychiatry.
[6] P. Renshaw,et al. Quantitation of dexfenflurainine/d‐norfenfluramine concentration in primate brain using 19F NMR spectroscopy , 1998, Magnetic resonance in medicine.
[7] R. Post,et al. Functional Brain Imaging, Limbic Function, and Affective Disorders , 1996 .
[8] B. Mazoyer,et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine , 1999, Biological Psychiatry.
[9] R. Turner,et al. Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[10] J S Duncan,et al. Positron emission tomography receptor studies in epilepsy. , 1999, Revue neurologique.
[11] L. Altshuler,et al. T2 hyperintensities in bipolar disorder: magnetic resonance imaging comparison and literature meta-analysis. , 1995, The American journal of psychiatry.
[12] Melissa P. DelBello,et al. MRI Analysis of the Cerebellum in Bipolar Disorder: A Pilot Study , 1999, Neuropsychopharmacology.
[13] J. Soares,et al. The anatomy of mood disorders—review of structural neuroimaging studies , 1997, Biological Psychiatry.
[14] S. Raz. Structural Brain Abnormalities in the Major Psychoses , 1989 .
[15] L W Jelinski,et al. Nuclear magnetic resonance spectroscopy. , 1995, Academic radiology.
[16] P R Luyten,et al. Broadband proton decoupling in human 31p NMR spectroscopy , 1989, NMR in biomedicine.
[17] P F Renshaw,et al. In vivo detection of GABA in human brain using a localized double‐quantum filter technique , 1997, Magnetic resonance in medicine.
[18] S. Rauch,et al. Neuroimaging and Neurobiological Models of Depression , 1997, Harvard review of psychiatry.
[19] K. Krishnan,et al. Structural changes in the brain of patients with bipolar affective disorder by MRI: A review of the literature , 1997, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[20] J. Price,et al. Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders , 1998, Molecular Psychiatry.
[21] R. Shulman,et al. Localized 1H NMR spectra of glutamate in the human brain , 1992, Magnetic resonance in medicine.
[22] B. Rosen,et al. Susceptibility contrast imaging of cerebral blood volume: Human experience , 1991, Magnetic resonance in medicine.
[23] J. Schmahmann,et al. The cerebellar cognitive affective syndrome. , 1998, Brain : a journal of neurology.
[24] H. Nasrallah,et al. Cortical atrophy in schizophrenia and mania: a comparative CT study. , 1982, The Journal of clinical psychiatry.
[25] K. Botteron,et al. MRI abnormalities in adolescent bipolar affective disorder. , 1992, Journal of the American Academy of Child and Adolescent Psychiatry.
[26] R. Kikinis,et al. Subgenual cingulate cortex volume in first-episode psychosis. , 1999, The American journal of psychiatry.
[27] S. Dager,et al. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. , 1998, The American journal of psychiatry.
[28] Z. Szabo,et al. Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.
[29] Hermann-Josef Gertz,et al. Positive correlation between reduction of handwriting area and D2 dopamine receptor occupancy during treatment with neuroleptic drugs , 1999, Psychiatry Research: Neuroimaging.
[30] M. Iyo,et al. Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β‐CFT binding with positron emission tomography , 1999, Annals of neurology.
[31] L. DeLisi,et al. Computed tomography in schizophreniform disorder and other acute psychiatric disorders. , 1982, Archives of general psychiatry.
[32] M. Kraut,et al. Kinetic Analysis of [11C]McN5652: A Serotonin Transporter Radioligand , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] S. Lippmann,et al. Cerebellar vermis dimensions on computerized tomographic scans of schizophrenic and bipolar patients. , 1982, The American journal of psychiatry.
[34] P. Videbech. MRI findings in patients with affective disorder: a meta‐analysis , 1997, Acta psychiatrica Scandinavica.
[35] S. Bluml. In VivoQuantitation of Cerebral Metabolite Concentrations Using Natural Abundance13C MRS at 1.5 T , 1999 .
[36] N Sailasuta,et al. Proton spectroscopy without water suppression: The oversampled J‐resolved experiment , 1998, Magnetic resonance in medicine.
[37] P. Renshaw,et al. Differences in Cerebellar Blood Volume in Schizophrenia and Bipolar Disorder , 1998, NeuroImage.
[38] J. Ehrhardt,et al. Structural brain abnormalities in bipolar affective disorder. Ventricular enlargement and focal signal hyperintensities. , 1990, Archives of general psychiatry.
[39] H. Pasantes‐Morales,et al. Taurine: an osmolyte in mammalian tissues. , 1998, Advances in experimental medicine and biology.
[40] K. Krishnan,et al. Subcortical hyperintensities on brain magnetic resonance imaging: a comparison of normal and bipolar subjects. , 1991, The Journal of neuropsychiatry and clinical neurosciences.
[41] R B Noto,et al. Advances in nuclear medicine: current concepts. , 1999, Medicine and health, Rhode Island.
[42] J D Speelman,et al. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I]FPCIT SPECT. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[43] N. Raz,et al. Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging. , 1990, Psychological bulletin.
[44] J A Sorenson,et al. 3D localized 2D NMR spectroscopy on an MRI scanner. , 1995, Journal of magnetic resonance. Series B.
[45] Hitoshi Shinotoh,et al. Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age , 1999, European Journal of Nuclear Medicine.
[46] A. J. Kumar,et al. Basal ganglia volumes and white matter hyperintensities in patients with bipolar disorder. , 1994, The American journal of psychiatry.
[47] T. Inubushi,et al. Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder , 1994, Psychiatry Research: Neuroimaging.
[48] Michael J. Berridge,et al. Neural and developmental actions of lithium: A unifying hypothesis , 1989, Cell.
[49] P. Renshaw,et al. Applications of functional MR imaging to research in psychiatry. , 1999, Neuroimaging clinics of North America.
[50] P. Murali Doraiswamy,et al. Brain imaging in clinical psychiatry , 1997 .
[51] S. Barondes. Report of the National Institute of Mental Health’s Genetics Workgroup Introduction , 1999, Biological Psychiatry.
[52] Karl J. Friston,et al. Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.
[53] R. Hales,et al. J Neuropsychiatry Clin Neurosci , 1992 .
[54] M. Garwood,et al. Simultaneous in vivo spectral editing and water suppression , 1998, NMR in biomedicine.
[55] J. Zubieta,et al. Gender and age influences on human brain mu-opioid receptor binding measured by PET. , 1999, The American journal of psychiatry.
[56] K. Krishnan,et al. Nuclear magnetic resonance spectroscopy: new insights into the pathophysiology of mood disorders. , 1996, Depression.
[57] J. Lieberman,et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. , 1994, The American journal of psychiatry.
[58] Chie Seki,et al. Effect of tracer metabolism on PET measurement of [11C]pyrilamine binding to histamine H1 receptors , 1999, Annals of nuclear medicine.
[59] D. Kupfer,et al. Pet imaging of serotonin 1A receptor binding in depression , 1999, Biological Psychiatry.
[60] H. Okazawa,et al. The Validity of the PET/α [11C] Methyl-L-Serotonin Synthesis in the Human Brain , 1999, Neuropsychopharmacology.
[61] A. Stoll,et al. The human brain resonance of choline-containing compounds is similar in patients receiving lithium treatment and controls: An in vivo proton magnetic resonance spectroscopy study , 1992, Biological Psychiatry.
[62] C Crouzel,et al. Imaging central nicotinic acetylcholine receptors in baboons with [18F]fluoro-A-85380. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[63] B Vikhoff-Baaz,et al. Performance of 2D 1H spectroscopic imaging of the brain: some practical considerations regarding the measurement procedure. , 1999, Magnetic resonance imaging.
[64] M. Raichle,et al. Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.
[65] J Star-Lack,et al. High spatial resolution and speed in MRSI , 1997, NMR in biomedicine.
[66] M. Bárány,et al. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients , 1992, Schizophrenia Research.
[67] B. Rosen,et al. Functional mapping of the human visual cortex by magnetic resonance imaging. , 1991, Science.
[68] R. Baldessarini. Drugs and the treatment of psychiatric disorders , 1996 .
[69] K. Krishnan,et al. Hyperintense lesions on magnetic resonance images in bipolar disorder , 1999, Biological Psychiatry.
[70] R. Shulman,et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[71] P. Allen,et al. A new multiple quantum filter design procedure for use on strongly coupled spin systems found in vivo: Its application to glutamate , 1998, Magnetic resonance in medicine.
[72] A. Scialli. Goodman and Gilman's the pharmacologic basis of therapeutics , 1991 .
[73] P. Renshaw,et al. Applications of Dynamic Susceptibility Contrast Magnetic Resonance Imaging in Neuropsychiatry , 1996, NeuroImage.
[74] D. Wong,et al. Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. , 1999, Nuclear medicine and biology.
[75] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[76] B. Woods,et al. Structural brain abnormalities in first-episode mania , 1993, Biological Psychiatry.
[77] R. Heath,et al. Gross Pathology of the Cerebellum in Patients Diagnosed and Treated as Functional Psychiatric Disorders , 1979, The Journal of nervous and mental disease.
[78] H. Nasrallah,et al. Cerebral venticular enlargement in young manic males , 1982 .
[79] G. Pearlson,et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. , 1995, Archives of general psychiatry.
[80] G. Fein,et al. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. , 1995, The American journal of psychiatry.
[81] H. Nasrallah,et al. Cerebral ventricular enlargement in young manic males. A controlled CT study. , 1982, Journal of affective disorders.
[82] R. Langevin,et al. Deficits in gray matter volume are present in schizophrenia but not bipolar disorder 1 This work was presented at the Meeting of the Society of Biological Psychiatry, Philadelphia, PA, USA, May 1994. 1 , 1997, Schizophrenia Research.
[83] P. Grant,et al. Diffusion MR imaging. Theory and applications. , 1999, Neuroimaging clinics of North America.
[84] C. Parsons,et al. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. , 1999, Journal of receptor and signal transduction research.
[85] R. Robinson,et al. Manic-depressive and pure manic states after brain lesions , 1991, Biological Psychiatry.
[86] David C. Steffens,et al. Structural neuroimaging and mood disorders: Recent findings, implications for classification, and future directions , 1998, Biological Psychiatry.
[87] J. Mazziotta,et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. , 1989, Archives of general psychiatry.
[88] J. Karp,et al. In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates , 1999, European Journal of Nuclear Medicine.
[89] N. Andreasen,et al. Cerebellar atrophy in schizophrenia and affective disorder. , 1987, The American journal of psychiatry.
[90] J. Links,et al. Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. , 1985, Psychopharmacology bulletin.
[91] P Boesiger,et al. Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography. , 1999, Magnetic resonance imaging.
[92] Andrew W. Douglas,et al. MRI subcortical signal hyperintensities in Mania at first hospitalization , 1993, Biological Psychiatry.
[93] C. Hanstock,et al. Effects of lithium and amphetamine on inositol metabolism in the human brain as measured by 1H and 31P MRS , 1999, Biological Psychiatry.
[94] A. Snyder,et al. Quantitative diffusion-tensor anisotropy brain MR imaging: normative human data and anatomic analysis. , 1999, Radiology.
[95] M. Roy,et al. Dégénérescence cérébelleuse secondaire à une intoxication aiguë au lithium. , 1998 .
[96] S. Kennedy,et al. A Review of Functional Neuroimaging in Mood Disorders: Positron Emission Tomography and Depression , 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[97] J S Taylor,et al. Proton‐decoupled 31P chemical shift imaging of the human brain in normal volunteers , 1993, NMR in biomedicine.
[98] Justin S. Smith,et al. Quantification of δ-Opioid Receptors in Human Brain with N1′ -([11C]Methyl) Naltrindole and Positron Emission Tomography , 1999 .
[99] W C Eckelman,et al. Using single photon emission tomography (SPECT) and positron emission tomography (PET) to trace the distribution of muscarinic acetylcholine receptor (MACHR) binding radioligands. , 1999, Life sciences.
[100] Richard J Davidson,et al. Regional brain function, emotion and disorders of emotion , 1999, Current Opinion in Neurobiology.
[101] P. Renshaw,et al. Effects of myo-Inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study , 1999, Biological Psychiatry.
[102] J. Mann,et al. The functional neuroanatomy of mood disorders. , 1997, Journal of psychiatric research.
[103] D. Jeste,et al. Neuroanatomical Studies of Major Affective Disorders , 1988, British Journal of Psychiatry.
[104] S. Rauch,et al. Clinical Neuroimaging in Psychiatry , 1995, Harvard review of psychiatry.
[105] W. Yates,et al. Cardiovascular risk factors in affective disorder. , 1987, Journal of affective disorders.